This guide explains how to establish and reproduce the experimental autoimmune myasthenia gravis (EAMG) model using the AChR α(97–116) peptide, covering the immunization protocol in C57BL/6 mice, clinical scoring and model evaluation, and practical troubleshooting tips for reproducible myasthenia gravis research.

This article provides a comprehensive standard operating procedure (SOP) for THP-1 cell culture, covering thawing, passaging, cryopreservation, and key considerations such as medium preparation, cell density control, and PMA-induced differentiation, helping researchers maintain cell quality and experimental reproducibility.

A study published in Advanced Science reported a CD28-targeted, enzyme-responsive conformation-switching self-assembling peptide for selective T-cell acute lymphoblastic leukemia (T-ALL) therapy. The peptide binds CD28 on leukemic T cells and undergoes enzyme-triggered in situ self-assembly in the tumor microenvironment, achieving selective antitumor activity with minimal off-target effects.

A study published in PNAS revealed that tissue factor pathway inhibitor 2 (TFPI2) promotes natural killer (NK) cell–mediated killing of glioblastoma (GBM) cells. Upon contact with GBM cells, NK cells secrete IL-1β and TNF-α, which activate NF-κB signaling in tumor cells and induce TFPI2 expression. TFPI2 enhances NK cell adhesion to GBM cells while suppressing the immune checkpoint TIGIT, offering a promising strategy to improve NK cell–based immunotherapy for glioblastoma.

A joint study published in ACS Nano engineered a Pt(IV) cisplatin prodrug into a lipid nanoparticle (LNP) helper lipid for co-delivery of Xkr8 siRNA and ANX5 mRNA. The integrated PtLNP system blocks phosphatidylserine externalization through two parallel pathways, reshapes the tumor immune microenvironment, and achieves sustained tumor inhibition with durable antitumor immune memory.